← ANALYST RATINGS · TIPRANKS
Oruka Therapeutics (ORKA): analyst forecast and price target
Analyst consensus
Strong Buy11 Buy0 Hold0 Sell
Ratings of 11 analysts in the last 3 months12-month forecast
Based on 11 price targets given in the last 3 months, the average target is $154, the highest $200, the lowest $120. The average is +114.8% from the last price of $71.93.
Analyst ratings 13
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $79.00 → $77.00−2.5% | Hold | +7.0% | Reiterated | 17.10.26on TipRanks 17:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $75.00 → $73.00−2.7% | Hold | +1.5% | Reiterated | 17.10.26on TipRanks 17:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $78.00 → $76.00−2.6% | Hold | +5.7% | Reiterated | 17.10.26on TipRanks 17:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $77.00 → $75.00−2.6% | Hold | +4.3% | Reiterated | 17.10.26on TipRanks 17:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $78.00 → $76.00−2.6% | Hold | +5.7% | Reiterated | 17.10.26on TipRanks 17:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $77.00 → $75.00−2.6% | Hold | +4.3% | Reiterated | 17.10.26on TipRanks 17:05 | — | |
| Yasmeen Rahimi★★★★★★★★★★#160 · hits 51% · avg +36.0% | Piper Sandler | $180 | Buy | +150.2% | Reiterated | 07.10.26on TipRanks 07:25 | −0.6%next day −2.4% · 5 days −2.6% | ↗ |
| Julian Harrison★★★★★★★★★★#42 · hits 57% · avg +53.4% | BTIG | $151 | Buy | +109.9% | Reiterated | 01.10.26on TipRanks Oct 2 06:16 | 0.0%next day +0.6% · 5 days −8.7% | ↗ |
| Martin Fan★★★★★★★★★★#177 · hits 87% · avg +94.8% | Wedbush | $165 | Buy | +129.4% | Reiterated | 24.09.26on TipRanks 08:25 | −4.8%next day −1.7% · 5 days −2.0% | ↗ |
| Mitchell Kapoor★★★★★★★★★★#1086 · hits 45% · avg +12.2% | H.C. Wainwright | $120 | Buy | +66.8% | Reiterated | 24.09.26on TipRanks 06:25 | −4.8%next day −1.7% · 5 days −2.0% | ↗ |
| Sam Slutsky★★★★★★★★★★#35 · hits 55% · avg +49.4% | LifeSci Capital | $175 | Buy | +143.3% | Reiterated | 23.09.26on TipRanks 12:55 | −4.2%next day −4.8% · 5 days −6.7% | ↗ |
| Kaveri Pohlman★★★★★★★★★★#1640 · hits 40% · avg +12.9% | Clear Street | $131 | Buy | +82.1% | Reiterated | 23.09.26on TipRanks 09:35 | −4.2%next day −4.8% · 5 days −6.7% | ↗ |
| Etzer Darout★★★★★★★★★★#105 · hits 63% · avg +31.4% | Barclays | $160 | Buy | +122.4% | Reiterated | 21.09.26on TipRanks 04:15 | −3.2%next day +1.3% · 5 days −8.8% | ↗ |
| Michael Yee★★★★★★★★★★#3077 · hits 49% · avg +3.8% | UBS | $130 | Buy | +80.7% | Reiterated | 01.09.26on TipRanks 19:25 | −1.0%next day −1.7% · 5 days +1.0% | ↗ |
| Tyler Van Buren★★★★★★★★★★#42 · hits 64% · avg +38.8% | TD Cowen | — | Buy | — | Reiterated | 26.08.26on TipRanks 08:15 | −2.4%next day −3.6% · 5 days −7.7% | ↗ |
| Roger Song★★★★★★★★★★#4779 · hits 41% · avg +2.6% | Jefferies | $133 | Buy | +84.9% | Reiterated | 11.08.26on TipRanks 10:55 | −0.1%next day +2.4% · 5 days +8.4% | ↗ |
| Yatin Suneja★★★★★★★★★★#120 · hits 57% · avg +33.0% | Guggenheim | $200 | Buy | +178.0% | Reiterated | 10.08.26on TipRanks Aug 11 07:10 | +6.4%next day −0.1% · 5 days +7.2% | ↗ |
| Alex Thompson CFA★★★★★★★★★★#60 · hits 73% · avg +50.6% | Stifel Nicolaus | $150 | Buy | +108.5% | Reiterated | 29.06.26on TipRanks 04:30 | +0.4%next day +2.1% · 5 days −9.5% | ↗ |
| David Risinger★★★★★★★★★★#64 · hits 65% · avg +33.1% | Leerink Partners | — | Buy | — | Reiterated | 02.06.26on TipRanks Jun 4 22:30 | +0.3%next day +4.3% · 5 days +24.1% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Oruka Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $154 at a price of $83.29 (+85.5%); now: $154 at $71.93 (+114.8%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 26 | 24 | 14 | 13 | 13 | 13 |
| Buy | 10 | 9 | 4 | 7 | 9 | 8 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 18.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.60 (from $-0.79 to $-0.32). Last quarter: $-0.55.
Best top-analyst consensus in the sector · Healthcare
About Oruka Therapeutics
- CEO: Lawrence Otto Klein
- Employees: 68
- 855 Oak Grove Avenue, Menlo Park, CA, 94025, US
- www.orukatx.com
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Data from the stock’s TipRanks forecast page, read 80 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗